Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-Current Assets (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Non-Current Assets for 12 consecutive years, with $9.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 38.94% year-over-year to $9.0 million, compared with a TTM value of $44.6 million through Sep 2025, down 33.71%, and an annual FY2024 reading of $13.2 million, down 29.85% over the prior year.
  • Non-Current Assets was $9.0 million for Q3 2025 at CytomX Therapeutics, down from $10.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $131.4 million in Q2 2021 and bottomed at $9.0 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $31.9 million, with a median of $21.4 million recorded in 2023.
  • The sharpest move saw Non-Current Assets surged 273.41% in 2021, then tumbled 79.87% in 2022.
  • Year by year, Non-Current Assets stood at $29.1 million in 2021, then dropped by 18.28% to $23.8 million in 2022, then fell by 20.74% to $18.9 million in 2023, then fell by 29.85% to $13.2 million in 2024, then tumbled by 31.68% to $9.0 million in 2025.
  • Business Quant data shows Non-Current Assets for CTMX at $9.0 million in Q3 2025, $10.4 million in Q2 2025, and $11.9 million in Q1 2025.